Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.
Explore this paper's citation graph
- Published
- 2015-01-01
- Cited by
- 1,893
- References
- 0
- Access
- Open access
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:35325078
References
No references recorded for this paper.
Cited by
- Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
- Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience
- Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation
- mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis
- Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis
- Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice
- The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers
- Mesenchymal Stem Cells in Fibrotic Disease.
- A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure
- Nintedanib in Severe Idiopathic Pulmonary Fibrosis: Effectiveness through Compassion
- Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
- Nailfold Videocapillaroscopy as a Candidate Biomarker for Organ Involvement and Prognosis in Patients with Systemic Sclerosis
- New Data in IPF: A Pivotal Change in the future of IPF Treatment
- Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis
- Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT)
- Idiopathic Pulmonary Fibrosis - Diagnosis and Treatment
- CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice
- Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
- Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis
- Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs
Related papers
No related papers recorded.